US OptionsDetailed Quotes
LFCR241018C10000
- 0.13
- -0.21-61.76%
15min DelayClose Sep 27 16:00 ET
0.15High0.13Low
0.13Open0.34Pre Close5 Volume13 Open Interest10.00Strike Price68.00Turnover221.16%IV104.65%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type0.1277Delta0.0837Gamma38.08Leverage Ratio-0.0136Theta0.0003Rho4.86Eff Leverage0.0024Vega
Lifecore Biomedical Stock Discussion
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
Lifecore Biomedical (NASDAQ: LFCR) reported its fiscal year 2024 results, showing strong revenue growth of 24.2% to $128.3 million.
The company's CDMO business grew 27%, while its HA raw material manufacturing increased 18%.
Gross profit rose 49.5% to $41.9 million, with margin expanding to 32.6%.
Key highlights include:
Net income from con...
$American International Group (AIG.US)$ $Bioventus (BVS.US)$ $CohBar (CWBR.US)$ $HeartCore Enterprises (HTCR.US)$ $Intuit (INTU.US)$ $Lifecore Biomedical (LFCR.US)$ $Lipocine (LPCN.US)$ $Microbot Medical (MBOT.US)$ $Ocean Biomedical (OCEA.US)$ $Palo Alto Networks (PANW.US)$ $RenaissanceRe Holdings (RNR.US)$ $SunCar technology (SDA.US)$ $Sysco Corp (SYY.US)$ $TEMA MONOPOLIES AND OLIGOPOLIES ETF (TOLL.US)$ $Western Digital (WDC.US)$
150M$ refinancing deal
No comment yet